IRIS
STAGNO, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.078
AS - Asia 1.641
NA - Nord America 715
SA - Sud America 467
AF - Africa 59
OC - Oceania 3
Totale 4.963
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.653
SG - Singapore 708
US - Stati Uniti d'America 641
BR - Brasile 382
CN - Cina 346
HK - Hong Kong 252
IT - Italia 138
VN - Vietnam 137
DE - Germania 79
FR - Francia 54
IN - India 46
MX - Messico 35
GB - Regno Unito 33
AR - Argentina 31
CA - Canada 25
BD - Bangladesh 24
AT - Austria 23
NL - Olanda 21
TR - Turchia 21
ZA - Sudafrica 18
IQ - Iraq 16
ID - Indonesia 14
FI - Finlandia 13
EC - Ecuador 12
JP - Giappone 12
PL - Polonia 11
TN - Tunisia 11
PK - Pakistan 10
UA - Ucraina 10
CL - Cile 9
MA - Marocco 9
PE - Perù 9
VE - Venezuela 9
SE - Svezia 8
CO - Colombia 7
AZ - Azerbaigian 6
ES - Italia 6
PH - Filippine 6
UZ - Uzbekistan 6
PT - Portogallo 5
UY - Uruguay 5
DZ - Algeria 4
EG - Egitto 4
IL - Israele 4
PA - Panama 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
GE - Georgia 3
IE - Irlanda 3
JO - Giordania 3
KE - Kenya 3
LT - Lituania 3
MY - Malesia 3
NP - Nepal 3
AU - Australia 2
BE - Belgio 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EE - Estonia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NR - Nauru 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TW - Taiwan 1
Totale 4.963
Salva come PNG Salva come JPEG
Città #
Moscow 501
Singapore 361
Hong Kong 250
Ashburn 124
Beijing 105
Ho Chi Minh City 55
Messina 53
Los Angeles 49
San Jose 47
São Paulo 36
Hanoi 29
Dallas 28
Council Bluffs 27
Munich 25
New York 24
Guangzhou 22
Nuremberg 21
Mexico City 20
Santa Clara 19
Frankfurt am Main 18
Vienna 17
Orem 16
Amsterdam 15
Rio de Janeiro 15
Lauterbourg 14
Redondo Beach 14
Rome 14
Brooklyn 13
Buffalo 13
Johannesburg 13
Montreal 13
Shanghai 13
Milan 12
Porto Alegre 12
Tianjin 12
Atlanta 10
Chennai 10
Tokyo 10
Belo Horizonte 9
Boston 9
Catania 9
Haiphong 9
Mumbai 9
Palermo 9
Warsaw 9
Da Nang 8
Poplar 8
Stockholm 8
Brasília 7
Chicago 7
Düsseldorf 7
Helsinki 7
Santo André 7
Tunis 7
Baghdad 6
Dhaka 6
Lima 6
Nova Iguaçu 6
San Francisco 6
Seattle 6
Tashkent 6
The Dalles 6
Baku 5
Bexley 5
Curitiba 5
Denver 5
Franca 5
Manchester 5
Natal 5
New Delhi 5
Paris 5
Shenzhen 5
São José dos Campos 5
Ankara 4
Bauru 4
Guarulhos 4
Houston 4
Istanbul 4
Jakarta 4
Lahore 4
Limina 4
London 4
Panama City 4
Phoenix 4
Quito 4
Trapani 4
Barretos 3
Bắc Ninh 3
Campinas 3
Caracas 3
Dublin 3
Erbil 3
Garanhuns 3
Guayaquil 3
Hải Dương 3
Iguaí 3
Jeddah 3
Joinville 3
Medellín 3
Montevideo 3
Totale 2.376
Salva come PNG Salva come JPEG
Nome #
Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw 108
Influence of Vitamin D and Its Analogues in Type-B Lymphomas 107
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 104
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 96
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 95
Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors 89
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 85
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 84
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 83
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 83
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 82
Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms 81
Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment 79
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 78
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 77
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study 77
A case of high-risk AML in a patient with advanced systemic mastocytosis 74
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 73
A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy 72
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 71
Gut Microbiota Dysbiosis and Dietary Interventions in Non-Hodgkin B-Cell Lymphomas: Implications for Treatment Response 70
All-trans-retinoic-acid- and growth-factor-mediated induction of alkaline phosphatase activity in freshly isolated chronic myeloid leukemia cells 70
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 70
Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management 68
Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea [5] 68
Biochemical fingerprinting of dried blood serum from chronic lymphocytic leukemia patients by Raman spectroscopy: Towards prognostic classification 67
Bispecific Antibodies and Antibody–Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma 67
All-trans retinoic acid might also induce apoptosis in freshly isolated chronic myeloid leukemia cells 67
Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia 66
Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies 64
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells 62
Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation 62
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 61
Curcumin and Acute Myeloid Leukemia: Synergistic Effects with Targeted Therapy 60
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey 57
Decoding Immunodeficiencies with Artificial Intelligence: A New Era of Precision Medicine 57
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications 57
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 56
Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells 55
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 55
Biochemical fingerprinting of dried blood serum from chronic lymphocytic leukemia patients by Raman spectroscopy: Towards prognostic classification 54
Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia 52
The Q-LAMP method represents a valid and rapid alternative for the detection of the BCR-ABL1 rearrangement in Philadelphia-positive Leukemias 52
Septic Shock in Hematological Malignancies: Role of Artificial Intelligence in Predicting Outcomes 51
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up 51
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 51
Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia 49
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 47
Modeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems 46
Chk1 inhibition restores inotuzumab ozogamicin citotoxicity in CD22-positive cells expressing mutant p53 46
CD34 expression in adult acute lymphoblastic leukemia 44
Uncommon long-term survival in a patient with chronic myeloid leukemia 43
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib 42
T cell receptor δ-chain gene rearrangement in a novel case of adult NK cell leukemia 40
Cutaneous vasculitis in non Hodgkin's lymphoma 40
Phenotypic and functional alterations of innate lymphoid cells in hematological malignancies: potential clinical application 37
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib 37
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 37
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia 37
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 34
Nilotinib 300 mg twice daily: An academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients 33
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 30
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib 30
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 29
Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population 28
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 27
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database 27
Infliximab therapy in hematologic malignancies: Handle with care (Comment) 26
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 26
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 26
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 25
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study 24
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients 23
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 23
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection 23
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 23
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 22
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 22
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 22
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 22
Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia 22
Oxidative Stress and Mitochondrial Dysfunction in Myelodysplastic Syndrome: Roles in Development, Diagnosis, Prognosis, and Treatment 21
Efficacy of nilotinib in a CML patient expressing the three-way complex variant translocation t(2;9;22) 21
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 21
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 21
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 20
Myeloid Derived Suppressor Cells (MDSCs) are increased and exert immunosuppressive activity together with Polymorphonuclear Leukocytes (PMNs) in chronic myeloid leukemia patients 20
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 20
Dasatinib first-line: Multicentric Italian experience outside clinical trials 20
Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study 19
Efficacy of dasatinib in a very elderly CML patient expressing a rare E13A3 BCR-ABL1 fusion transcript: A case report 19
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 18
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 18
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2‑OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 18
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up 18
Guidelines for the management of pleural effusions during dasatinib treatment in chronic myeloid leukemia 18
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 17
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 17
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 17
Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy 17
Totale 4.740
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.586
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.586
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202429 0 0 0 0 0 0 0 0 0 11 2 16
2024/20251.149 20 0 0 24 54 17 149 137 264 81 126 277
2025/20264.054 146 223 229 331 365 898 363 569 618 312 0 0
Totale 5.232